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 Caseous lymphadentitis (CLA) caused by the Gram Positive bacteria Corynebacterium 14 
pseudotuberculosis has been present in the UK since the 1980s and is now considered 15 
endemic. CLA is considered to be an iceberg disease i.e. production limiting disease, 16 
characterised by slow insidious onset, and production limiting effects in a larger 17 
proportion of the flock than that exhibiting clinical signs at any given point in time. The 18 
disease was previously reviewed in InPractice by Baird (2003) so we will consider updates 19 
in our understanding of the pathology, risk factors for flocks and the challenges of 20 
initiating control where the cost of the disease is still relatively unquantified.  21 
 22 
Pathogenesis 23 
Animals become infected by either inhalation or via skin abrasions  where the bacteria 24 
releases the exotoxin phospholipase D (PLD) and mycolic acid resulting in surface necrosis; 25 
increased vascular permeability, resulting in infection of phagocytes. Phospholipase D is a 26 
chemotaxonomic factor which impairs chemotaxis of neutrophils (Baird and Fontaine, 27 
2007). Whilst these lesions may be confined to superficial lesions, migration of infected 28 
phagocytes to regional lymph nodes can result in lymph node destruction and further 29 
infection of phagocytes.  CLA infection results in chronic granulomatous lesions known 30 
commonly as “cheesy gland” due to accumulation of infected phagocytes, eosinophils and 31 
cellular debris forming distinct abscesses with multi-centric layers (see figure 1). 32 
Figure 1: A mesenteric lymph node with CLA showing concentric rings (source Delia Lacasta, 33 
University of Faculty of Veterinary Medicine, University of Zaragoza) 34 
 35 
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 Lesions fistulate permitting bacterial dissemination i.e. through the skin allowing abscesses 36 
to drain or mediastinal abscesses fistulating into the bronchi to permit aerosolisation.  37 
 38 
Both visceral and superficial lymph nodes can be affected with the anatomical location 39 
apparently linked to the geographical location of the animals. UK lesions tend to be 40 
associated with superficial lymph nodes around the head and neck with Australian lesions 41 
more commonly linked with the torso, popliteal, prescapular and prefemoral lymph nodes 42 
(Binns, Bailey and Green, 2002; Baird, 2007). Additional locations described include the 43 
udder, upper respiratory tract (see figure 2) and kidneys (Ferrer et al., 2009) (see figure 3). 44 
Remnants of superficial lesions which have healed may be visible as scarring (figure 4). 45 
 46 
Figure 2: A mediastinal lymph node with CLA (source Delia Lacasta, University of Faculty of 47 
Veterinary Medicine, University of Zaragoza) 48 
 49 
Figure 3: Renal invasion with CLA (source Delia Lacasta, University of Faculty of Veterinary 50 
Medicine, University of Zaragoza) 51 
 52 
Figure 4: A ewe with evidence of old CLA lesions i.e. scarring over lymph node site 53 
 54 
Risk factors for transmission 55 
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Spread of the infection can be direct i.e. close contact with neighbouring animals or indirect 56 
contact via fomites. There is evidence that risk of abscess development is likely to be 57 
proportional to the inoculating dose and that some animals will clear infections but still be 58 
seropositive on screening (Batey, 1986).  59 
 60 
Risk factors for spread are largely related to the large volumes of infectious material yielded 61 
from ruptured abscesses and inhalation as a consequence of aerosolisation of internal 62 
lesions. 63 
 64 
 65 
Baird (2000) found that rams were significantly more likely to be seropositive than ewes in 66 
the same flock and it has been suggested that this may reflect behaviour within ram mobs 67 
i.e. fighting leading to ruptured abscesses and infection spread.  With regards to fomites, 68 
Corynebacterium pseudotuberculosis has been reported to survive in the environment for 55 69 
days in organic materials and that low environmental temperatures favour survival. 70 
Furthermore Windsor (2011) demonstrated the pathogen can survive in sheep dip for 2 71 
hours post inoculation. Shearing sheep with abscesses or plunge dipping of sheep with 72 
draining tracts along with non-infected flock mates are known to be risk factors. 73 
 74 
 75 
 76 
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Clearly, buying in infected animals with an unknown status is a risk factor for introducing 77 
CLA into naïve flocks and given the stratified system of flocks within the UK, movements are 78 
a significant risk factor for the UK. The work from Baird et al., (2004) suggests that rams 79 
therefore have an important role as sentinels for appraising flock health status and 80 
screening rams at purchase is important for reducing the risk of introducing infected 81 
animals. 82 
 83 
Corynebacterium pseudotuberculosis infections have been reported in humans where there 84 
is a high exposure to infected sheep or they are employed in high risk occupations such as 85 
livestock workers and butchers (Peel et al., 1997, Bregenzer et al., 1997) but these are often 86 
isolated incidents. 87 
 88 
 89 
Prevalence 90 
At a national level VIDA (Veterinary Investigation Diagnosis Analysis) data based on 91 
diagnoses is available (See figure 5), but this is likely to be an underestimate of the national 92 
situation. Small studies have been published which provide an indication of prevalence.  93 
Baird et al., (2004) looked at terminal sire flocks and found that >18% of flocks had at least 94 
one seropositive ram on screening. The overall population prevalence was found to be 95 
9.93% prevalence (95% CI 8.76-11.1 per cent) (Baird et al., 2004) with 18% of flocks having 96 
at least one positive animal and 36% flocks of these having more than one positive animal.   97 
 98 
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More recent work in the UK suggested a flock prevalence of 4% based upon the 99 
identification of macroscopic CLA lesions (superficial and visceral) detected during post-100 
mortem examination and confirmed by culture (P Davies, unpublished data). The sampling 101 
frame from which this data was derived involved a convenience sample of 56 flocks from 102 
England, Scotland and Wales. Each flock supplied between 12- 25 cull ewes for post-mortem 103 
examination by Farm Animal Post Mortems Ltd. The flocks represented a wide variety of 104 
breeds with a bias towards lowland breeds and were distributed throughout the high sheep 105 
density areas of the mainland UK. However, the Davies et al data required farmer 106 
cooperation in the participation and submission of cull ewes. Therefore, this data cannot be 107 
regarded necessarily as a representative sample of UK flocks. Furthermore, the diagnosis of 108 
CLA was based upon presence of lesions visible to the pathologist conducting the 109 
examination. This contrasts with the serological approach adopted by previous studies. This 110 
contracting methodology would be expected to be less sensitive but more specific than 111 
serological studies. This complements data collected in a fallen stock survey which found 112 
<1% of carcasses positive for CLA lesions on gross post-mortem (Lovatt and Strugnell., 113 
2013). However, when uncontrolled in flocks, 60% of adults can become seropositive (Binns 114 
et al., 2002). To date in the UK, no CLA prevalence study has been conducted using a truly 115 
randomised sampling frame.   116 
 117 
Figure 5: Graph to show VIDA diagnoses submitted through APHA 118 
 119 
 120 
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Productivity losses 121 
CLA is often listed as an “iceberg disease” along with Maedi Visna and Ovine Pulmonary 122 
Adenomatosis causing prematurely thin ewe syndrome i.e. emaciation in absence of other 123 
pathology and with normal nutrition.  The iceberg nature i.e. clinical cases being an indicator 124 
of many more subclinical cases, makes identification and eradication of subclinical infected 125 
animals important for disease management on farm. Thin ewes with CLA are more 126 
commonly associated with the visceral form of CLA.  Arsenault et al., (2003) showed that 127 
38.5% of animals with superficial lesions had visceral lesions on post-mortem inspection at 128 
the abattoir in Canada. 129 
 130 
Where CLA is endemic in flocks, economic costs are associated with premature culling, 131 
reduced milk yields, and documented reductions in wool yields. Whilst all the of work done 132 
looking at reduced wool crops is Australian, the reductions of 0.2-0.25kg per head and 133 
overall reduction by 4-7% (Windsor, 2011) of clean fleece are likely to indicate the 134 
physiological impact of CLA on individual sheep that may well be correlated with reduced 135 
production in other areas such as milk yield and fecundity. More research is required to 136 
understand the significance of these physiological impacts in the context of the UK sheep 137 
sector. 138 
 139 
CLA is a challenge for the processing sector as documented in Canada and Australia 140 
(Arsenault et al., 2003, Windsor and Bush, 2016) with lesions at risk of rupturing whilst on 141 
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the line resulting in carcass contamination in addition to trimming due to the presence of a 142 
lesion. 143 
 144 
At the low prevalence suspected in the UK, the economic impact of CLA is poorly 145 
understood. However, CLA infection within a flock and particularly the presence of CLA 146 
lesions is detrimental to profitability of pedigree flocks due to the inability to sell affected 147 
animals through public sales. It will restrict export opportunities in some cases. 148 
 149 
Differential diagnoses 150 
When approaching individuals with a suspected abscess in the region of lymph nodes, other 151 
differential diagnoses should be considered. Investigation should be with care given the 152 
highly infectious nature of the purulent materials i.e. lesions should not be lanced to 153 
minimise the risk of spreading CLA. Fine needle aspiration of lesions is recommended before 154 
draining. Key differentials could include the following: 155 
 156 
Actinobacillosis i.e. granulomatous lesions infected with Actinobacillus lignieresii that results 157 
in a suppurative adenitis in the regional lymph nodes. This gram negative bacteria would be 158 
differentiable on fine needle aspirate and gram stain. 159 
 160 
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Salivary mucocoele are less common in sheep but may be an important differential in goats. 161 
The contents of these cysts will initially mimic saliva and be sterile but may become 162 
inspissated over time (Linklater and Smith, 1993). 163 
 164 
Actinomyces pyogenes: Lumpy jaw secondary to primary dental lesions or drench gun 165 
injuries may result in mandibular swelling with regional lymph node involvement. The 166 
involvement of the bone in the mandible or maxilla would move this up the differential list 167 
(see figure 6). 168 
 169 
Figure 6: Actinomyces pyogenes infection of the jaw. 170 
 171 
Morel’s disease: Staphylococcus aureus subsp. Anaerobius has been found to produce 172 
similar abscesses to CLA on the head and neck of goats and be reported at high prevalences 173 
within flocks. However, in contrast to CLA, Morel’s typically affects young goats, has a 174 
shorter incubation periods (<3 weeks) and lesions are not always located near lymph nodes 175 
(Szaluś-Jordanow et al., 2010) (see figure 7)). 176 
Figure 7:  Morel’s disease in a goat (source Jaroslaw Kaba, Faculty of Veterinary Medicine, 177 
Warsaw University of Live Sciences). 178 
Other differentials could include trauma, haematoma, healing fractures, granulomas or 179 
dermal cysts.  180 
 181 
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Diagnosis 182 
There are a range of ways in which CLA can be diagnosed. Lesions can be identified on 183 
clinical examination or post-mortem examination and bacteriology with isolation of the 184 
bacteria is considered gold standard. However, this proves challenging where internal 185 
abscesses are of concern or in live animals where lesions may take up to 6 months to 186 
appear. Furthermore, direct microscopy can be limited especially when sampling old and 187 
calcified lesions.  Haematology changes were described by Scott et al., (1997) in affected 188 
animals i.e. neutrophilia and lymphocytosis but these are non-specific changes. 189 
 190 
Serology  191 
The most common test currently used in the live animal is the ELISA, however clear 192 
communication of sensitivities and specificities to the farmer prior to tests being conducted 193 
is important. CLA stimulates both the humoral and cellular immunities and therefore IgG or 194 
IFN-γ can be measured as indicators of each respectively. Serology against exotoxin 195 
phospholipase D is the most commonly used test because of its cost efficacy and acceptable 196 
test performance (Sn 87%, Sp 98%, Voigt et al., 2012, ELLITEST CLA Hyphen, France). The 197 
low sensitivity is likely to be a reflection of the intracellular nature of the bacteria. The low 198 
specificity will reflect the potential confusion with other Corynebacterium and potentially 199 
vaccination (Oreiby, 2015). It is also recommended that only lambs over 6 months old 200 
should be tested using serology (Williamson, 2001). Furthermore, serological tests are not 201 
able to distinguish animals who have cleared infections and those with active lesions. 202 
Western Blot testing is often used as a confirmatory test to improve the specificity of results 203 
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found. Currently the only available vaccination (Glanvac; Zoetis) cannot be differentiated 204 
from natural infection on serology. 205 
Bulk milk tank testing has been developed for goats in Norway (Nagel-Alne et al., 2015) with 206 
sensitivity of 72.7% and specificity of 88.6% with respect to identified prevalences >2%. 207 
 208 
 209 
Interferon Gamma Testing 210 
 Interferon Gamma testing is in development (Sunil et al., 2008) with early sensitivities of 211 
91% and specificities of 98% demonstrated in vivo. A major advantage of IFN- γ testing is the 212 
increased sensitivity and being unaffected by the vaccinal status of the sheep.  In addition, it 213 
has early diagnostic capability being able to detect animals 5 days post infection ( in 214 
comparison with between 6-11 days post infection with the ELISA Paule et al., 2003). There 215 
is no correlation between the severity of lesion and either the level of sero-positivity or the 216 
level of IFN- γ positivity  217 
 218 
Box 1: An approach to CLA diagnosis in a commercial flock 219 
 220 
Flocks may trigger screening for multiple reasons. Flocks may be interested in pursuing high 221 
health status, may have been requested to demonstrate freedom from CLA pre-sale of animals 222 
or may be concerned after finding evidence of suspicious lesions.  223 
 224 
Gold standard diagnosis of CLA on farm would be isolation and culture of Corynebacterium 225 
pseudotuberculosis from lesions of affected animals. Abscesses should be conservatively 226 
aspirated to avoid further spread whilst diagnosis pending, an impression smear made, and 227 
the bacteria submitted on a plain swab. This approach can be applied to both live animal and 228 
post-mortem samples 229 
 230 
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When lesions are largely resolved i.e. scarred or where calcified serology should be 231 
considered. The ELISA with Western Blot to confirm infection in animals with a positive 232 
ELISA result for the identification of CLA positive animals.  233 
 234 
Cull ewe screening 235 
When trying to establish status for a flock with no history of lesions a cull animal screen with 236 
both physical and serological examination could be considered as is common practice with 237 
the other iceberg diseases. However we know that rams are valuable sentinels for flock and 238 
therefore annual tup screening could also be considered. 239 
 240 
Screening suspect clinical cases 241 
For all flocks, recommending isolation of any animals with suspicious lesions prior to 242 
sampling for culture is prudent. Ewes are most likely to be examined for CLA as single/small 243 
groups of incidental animals i.e. in an outbreak situation or as part of thin ewe screens post-244 
weaning at culling.  245 
 246 
Screening at introduction and biosecurity  247 
Where there is an absence of a history of CLA on farm and where a farm wants to preclude 248 
its introduction into a flock, screening on new animals on arrival and whilst in isolation is 249 
recommended. Due to the delays in seroconversion, repeat testing at a 12 week interval and 250 
whilst in isolation should be considered. A single sample may miss recently infected animals. 251 
Vaccination status should be established prior to sampling as false positives may occur where 252 
there has been a history of vaccination. 253 
 254 
Whilst movement of animals is the most obvious risk factor, fomites and persons should not 255 
be forgotten. Shearing equipment, shared handling facilities or handling infected animals and 256 
then clean ones subsequently may spread CLA. Where CLA is present in a flock, shearing 257 
older animals or those with lesions later on may reduce the risk of “nicking” abscesses and 258 
spreading infection to younger animals. All equipment including that of contractors should be 259 
thoroughly cleaned prior to use on all flocks.  260 
 261 
Crucially, abscesses should not be lanced as they release highly infectious material 262 
contaminating the environment and potentially increasing the risk of further cases. 263 
 264 
 265 
End of Box 1 266 
 267 
Treatment 268 
 269 
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Given the highly infectious nature of CLA, the risk of multi-systemic involvement and the 270 
inability to entirely eradicate infection, animals are not conventionally treated. Whilst in the 271 
literature there are references to the relatively high susceptibility of Corynebacterium 272 
pseudotuberculosis to antibiotics including penicillin, the thick nature of the abscess wall 273 
make treatment prohibitive Senturk and Temizel, 2006, Washburn et al., 2009, Selera et al., 274 
2016). 275 
 276 
Senturk and Temizel, (2006) attempted to treat animals with draining abscesses with 277 
Rifamycin and Oxytetracyline. Whilst the 10 day combined courses resolved gross lesions, 278 
bacteriological cure was not demonstrated and we must be mindful that it is not 279 
appropriate to use Rifamyin as it is not licensed in the UK and it is listed as a critically 280 
important antibiotic given its role in treating Mycobacterium tuberculosis and leprosy.  281 
 282 
Selera et al., (2016) attempted photodynamic therapy post-operatively after surgical 283 
draining of lymph nodes. There was no evidence of recurrence within the treated lymph 284 
nodes within 6 months of the procedure. Whilst this does not involve antibiotic therapy, this 285 
treatment by definition will not access internal abscesses.  286 
 287 
Given the good efficacy of vaccination for CLA compared to the very poor efficacy of 288 
antibiotic treatment, the authors do not consider it justifiable or prudent antibiotic 289 
stewardship to treat cases with antibiotics and would encourage an emphasis of flock level 290 
control and prevention measures.   291 
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 292 
Management 293 
Following initial diagnosis and investigation (see box 1), there are two main strategies 294 
described for management of CLA in commercial flocks: vaccination and test-and-cull. 295 
 296 
 297 
The vaccine available is a formalin inactivated exotoxin vaccine for PLD Glanvac 6 (Zoetis, 298 
Australia) with field trial results showing rates of protection from 25-90%. The vaccination is 299 
also a clostridial vaccination requiring annual boosting pre-lambing. It can be imported into 300 
the UK under license via the Veterinary Medicines Directorate as it is not commercially 301 
available in the UK. Vaccination has resulted in the near elimination of overt clinical signs 302 
associated with CLA in flocks using the vaccine correctly in Australia (Windsor, 2014). 303 
 304 
The advantages of using vaccination include that it reduces the number of animals with lung 305 
and skin lesions thus reducing challenge in the flock and rate of new infections. It will 306 
therefore reduce spread in a flock but is not able to eradicate disease entirely. Sustained 307 
vaccination is therefore required to reduce bacterial load within the flock i.e. protecting 308 
younger animals whilst older infected animals are progressively culled. However, we need 309 
to mindful and communicate the limitations of our understanding of the efficacy of Glanvac 310 
programmes in the absence of epidemiological trials conducted under UK management 311 
conditions, pathogen strain, host genetic susceptibility and transmission dynamics/infection 312 
pressure. It should also be clearly communicated to flocks that at the moment there is no 313 
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DIVA vaccine available. Whilst this may be of little importance in commercial flocks, this may 314 
be of imperative significance in those considering future export and informed consent 315 
should be sought. Vaccination can be used in adult animals to reduce infection burden 316 
permitting the serological screening of young animals pre-sale and may be most appropriate 317 
for flocks with confirmed disease wishing to reduce infectious load within the flock with an 318 
aspiration to sell either pre-vaccinated or pre-screened animals for sale. 319 
 320 
The protocol for vaccination is two doses, 4 weeks apart with an annual booster at least a 321 
month before lambing or shearing.  Strategies for application of vaccination are described in 322 
box 2. The vaccination experience in Australia has been that prior to vaccination 323 
introduction, flock prevalence was as high as 97% flocks (New South Wales) with the flock 324 
level prevalence 29% in 1995. Abattoir screening and recording was subsequently 325 
introduced and found to be as low as 17% of consignments had at least one lesion positive 326 
animal and 1.3% of all animals were lesion positive (Windsor, 2011). These results have 327 
been achieved despite a further piece of work demonstrated that just 12% of flocks used 328 
the vaccines as recommended (Paton et al., 2003). The prevalence was demonstrated to be 329 
lower when vaccines were used correctly.  330 
 331 
‘Test and cull’ has been used for control in commercial suckler sheep flocks using individual 332 
antibody ELISA (Baird and Malone (2010), Voigt et al., (2012)) and coupled with bulk milk 333 
tank serology in goat herds in Norway (Nagel-Alne et al (2015). This requires repeated 334 
serological testing of the adult flock with subsequent removal of any positive animals. 335 
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 336 
Voigt et al., (2012) demonstrated that they achieved flock sero-positivity reduction from 337 
10% to 0.4% within two years by blood sampling every three months and culling any 338 
seropositive or culture positive animals.  339 
 340 
However, there is a huge cost associated with this strategy (see table 1) (Baird and Malone 341 
(2010). There may be a premium obtainable for CLA negative flocks, however, in the 342 
absence of an accreditation scheme in the UK, there is no formal recognition, 343 
standardisation or quality control available. The test characteristics needs to be clearly 344 
explained as it is highly likely that false negatives will occur, prolonging the testing period 345 
and extending time to eradication and furthermore false positives will be taken which in 346 
itself may have consequences for the economic value of the flock. Additionally, as 347 
prevalence reduces, the relative proportion of false positives increased (which may be 348 
equally detrimental for flocks with high value individuals). We must also remember that 349 
prevalence is not static, and animals with false negative results or those only recently 350 
infected may propagate infection during the testing interval. CLA common in inguinal & 351 
scrotal lymph nodes of rams at breeding soundness exam but semen quality was normal & no 352 
organism excreted in semen (Gouletsou & Fthenakis, 2010) so CLA positive animals could be 353 
considered for semen collection or embryo flushing. 354 
 355 
Table 1: Examples of costs for a 300 ewe flock, with 60 replacements and 5 rams testing and 356 
removing after sequential rounds of testing. We have made the assumption that the starting 357 
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prevalence of CLA is 10% before the onset of testing and that given the sensitivity some 358 
animals will be missed at each round of testing. 359 
Testing 
round  
>12 weeks 
intervals 
Blood sampling 
cost 
(£5.80 per sample, 
SAC 2018, >40 
samples) 
Time to 
bleed 
animals 
(£100 per 
hour) 
Animals identified  
(87%) sensitivity 
(98% specificity) 
CLA positive animals 
remaining in the flock 
10% starting prevalence 
0    37 animals 
1  £2117 £500 32 animals true positive, 1 
false positive 
5 animals 
2 As above As above 4 animal true positive, <1 
false positive 
1 animal 
3 As above As above 87% chance of finding the 
remaining 1 animal 
 
Total £6351 £1500   
Total £7851    
 360 
 361 
 362 
 363 
 364 
 365 
 366 
 367 
 368 
 369 
Box 2: Application of vaccination in sheep flocks 
 
Glanvac 6 (Zoetis, Australia) is a multi-valent vaccine licensed for the use in flocks for 
control of caseous lymphadentitis in addition to clostridial management. The protocol 
requires 1ml of vaccine injected under the skin near the neck. The primary course is 
completed with a second vaccine four weeks later with recommended annual booster 
doses to control CLA. Injection site reactions are not uncommon with the vaccine. 
 
How the vaccine is applied within flocks requires clear communication and informed 
decision making between vets and farmers. 
 
• Whole flock vaccination with initial vaccination when replacements recruited to 
the flock 
 
• Rams have been shown to be high risk for becoming and propagating infection. 
Therefore some commercial flocks may choose to vaccinate rams to reduce 
propagation within ram mobs and reduce infection risk to the ewe mob. This will 
not limit the impact of CLA within the ewe flock 
 
• Flocks wishing to control CLA but sell stock which could be demonstrated to be 
free from disease may choose to vaccinate the adult flocks and retained 
replacements, leaving for young-stock for sale unvaccinated in the absence of a 
DIVA vaccination. These animals should be in strict isolation and ideally blood 
sampled twice 12 weeks apart as per the former SAC health scheme. This may 
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 371 
 372 
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 374 
 375 
Implications for flocks 376 
Although the suspected UK flock-level prevalence is low and the economic implications for 377 
CLA infection are not fully understood, sheep movements between infected and non-infected 378 
flocks means that the spread of CLA is very likely.The impact of this is described in 379 
Norwegian literature where test and cull had to begin after an outbreak of CLA in a “ram 380 
breeding circle” (Hektoen et al., 2012).  381 
 382 
A positive diagnosis of CLA on a farm may preclude the premises from exporting and 383 
furthermore preclude them from sales where “clear” animals are required. Formerly, there 384 
was an accreditation scheme available in the UK through the Scottish Agricultural College.  385 
The scheme was abandoned due to low uptake and difficulties in isolating new animals for 386 
long periods post-purchase to complete quarantine testing and the cost of two veterinary 387 
visits, 12 weeks apart to accredit a small number of rams. 388 
 389 
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There are limitations with all strategies of management for CLA. Whilst vaccination has been 390 
highly efficacious in the Australian situation, this has not been repeated in the UK and for 391 
those flocks who may require sero-negative status to permit export or because this is 392 
required from their customers, the lack of DIVA vaccine available may preclude this option. 393 
Test and cull may be a costly strategy given the sensitivity of the test and even after 394 
apparent “clearance of reactors” positive animals may still be found.  The lack of a strategy 395 
which is practical with clear cost benefit is compounded by the apparent inertness of CLA in 396 
the UK commercial market in contrast with MV, OPA, infectious lameness, resistance 397 
parasites etc and the difficulty in defining the cost of the disease. Whilst motivators in the 398 
UK have not been studies with regards to attitudes towards CLA, in the authors’ 399 
experiences, desire to sell “clean” stock, the visual nature of the disease in prized stock, 400 
avoiding comeback, protecting the breed brand and pride in the stock they sell are 401 
motivators for implementing any strategy. For some farmers the emotional/reputational 402 
cost of this disease may drive their decision making above the cost benefit. 403 
 404 
Summary 405 
Further work is needed to understand the economic impact and prevalence of CLA in the UK 406 
sheep flock and goat herd but initial work suggests that the prevalence of infected flocks is 407 
much lower than observed in Australia. Vaccination has been demonstrated to be highly 408 
efficacious in reducing prevalence of disease within infected flocks but this requires a period 409 
of sustained vaccination, client compliance and clear communication. If a declared ‘CLA-free 410 
status’ is the aim, other routes such as test and cull should be considered. The relatively low 411 
sensitivity of serological testing presents its own challenges and informed consent should be 412 
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sought before commencing whole flock testing as this may be a long and costly process. 413 
Whilst we suspect the national prevalence is low, there is also evidence that prevalence is 414 
high among ram breeders and terminal sire flocks in particular and therefore the role of 415 
rams in the spread of CLA should not be underestimated. Discussions can be initially 416 
triggered by vets at cull ewe screens or of rams at point of purchase but as described, the 417 
next step for flocks as to investigation and implementation of control can be a tricky 418 
decision. Often there are bigger, clearer threats to production but for businesses built on a 419 
reputation of higher health, elite stock, this may be just as damaging to their business. 420 
Ultimately in the absence of clear cost-benefit analysis based on observational data from 421 
the UK, CLA management should be a clearly communicated undertaking with defined, 422 
costed outcomes. 423 
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